These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15230722)

  • 41. Increased expression of the cyclin D1 gene in Barrett's esophagus.
    Arber N; Lightdale C; Rotterdam H; Han KH; Sgambato A; Yap E; Ahsan H; Finegold J; Stevens PD; Green PH; Hibshoosh H; Neugut AI; Holt PR; Weinstein IB
    Cancer Epidemiol Biomarkers Prev; 1996 Jun; 5(6):457-9. PubMed ID: 8781742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.
    Kuramochi H; Vallböhmer D; Uchida K; Schneider S; Hamoui N; Shimizu D; Chandrasoma PT; DeMeester TR; Danenberg KD; Danenberg PV; Peters JH
    J Gastrointest Surg; 2004 Dec; 8(8):1007-16; discussion 1016-7. PubMed ID: 15585388
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genomic alterations in malignant transformation of Barrett's esophagus.
    Riegman PH; Vissers KJ; Alers JC; Geelen E; Hop WC; Tilanus HW; van Dekken H
    Cancer Res; 2001 Apr; 61(7):3164-70. PubMed ID: 11306503
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Molecular alterations in Barrett's esophagus and adenocarcinoma].
    Ozawa S; Ando N; Kitagawa Y; Ueda M; Kitajima M
    Nihon Geka Gakkai Zasshi; 1999 Mar; 100(3):235-9. PubMed ID: 10379532
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
    Sanz-Ortega J; Hernández S; Saez MC; Sierra E; Sanz-Ortega G; Torres A; Balibrea JL; Sanz-Esponera J; Merino MJ
    Hepatogastroenterology; 2003; 50(50):404-7. PubMed ID: 12749233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The molecular biology of esophageal adenocarcinoma.
    Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
    J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use of imaging and biomarkers in diagnosing Barrett's esophagus and predicting the risk of neoplastic progression.
    Ramzan Z; Nassri AB; Huerta S
    Expert Rev Mol Diagn; 2014 Jun; 14(5):575-91. PubMed ID: 24831686
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
    Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beta 1 integrin expression in adenocarcinoma of Barrett's esophagus.
    Bottger TC; Youssef V; Dutkowski P; Seifert J; Maschek H; Brenner W; Junginger T
    Hepatogastroenterology; 1999; 46(26):938-43. PubMed ID: 10370643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p53-mutant clones and field effects in Barrett's esophagus.
    Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ
    Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas.
    Soldes OS; Kuick RD; Thompson IA; Hughes SJ; Orringer MB; Iannettoni MD; Hanash SM; Beer DG
    Br J Cancer; 1999 Feb; 79(3-4):595-603. PubMed ID: 10027336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. APC gene alterations in Barrett's metaplasia are implicated at an early stage in the carcinogenesis of esophageal adenocarcinoma.
    Fein M
    Am J Gastroenterol; 1997 Feb; 92(2):359-60. PubMed ID: 9040229
    [No Abstract]   [Full Text] [Related]  

  • 53. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
    Wilson KT; Fu S; Ramanujam KS; Meltzer SJ
    Cancer Res; 1998 Jul; 58(14):2929-34. PubMed ID: 9679948
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
    Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multistage carcinogenesis in Barrett's esophagus.
    Maley CC
    Cancer Lett; 2007 Jan; 245(1-2):22-32. PubMed ID: 16713672
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Barrett's esophagus. The significance of p53 in clinical practice.
    Ireland AP; Clark GW; DeMeester TR
    Ann Surg; 1997 Jan; 225(1):17-30. PubMed ID: 8998117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression.
    Maslyonkina KS; Konyukova AK; Alexeeva DY; Sinelnikov MY; Mikhaleva LM
    Cancer Med; 2022 Jan; 11(2):447-478. PubMed ID: 34870375
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Intraepithelial neoplasia of Barrett's esophagus: prognosis of potential malignancy].
    Werner M; Lassmann S
    Pathologe; 2011 Nov; 32 Suppl 2():197-201. PubMed ID: 22033682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytogenetic analysis of Barrett's mucosa and adenocarcinoma of the distal esophagus and cardia.
    Menke-Pluymers MB; van Drunen E; Vissers KJ; Mulder AH; Tilanus HW; Hagemeijer A
    Cancer Genet Cytogenet; 1996 Sep; 90(2):109-17. PubMed ID: 8830718
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of molecular biology in the follow-up of patients who have Barrett's esophagus.
    Casson AG
    Chest Surg Clin N Am; 2002 Feb; 12(1):93-111, ix-x. PubMed ID: 11901936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.